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ABSTRACT
The tumor microenvironment plays an important role in cancer progression. Here, 
we focused on the role of reactive mesenchymal stem cells (MSC) in osteosarcoma 
(OS), and used human adipose MSC and a panel of OS cell lines (Saos-2, HOS, and 
143B) to investigate the mutual effect of normal-cancer cell metabolic programming. 
Our results showed that MSC are driven by oxidative stress induced by OS cells 
to undergo Warburg metabolism, with increased lactate production. Therefore, we 
analyzed the expression of lactate monocarboxylate transporters. By real time PCR 
and immunofluorescence, in MSC we detected the expression of MCT-4, the transporter 
for lactate efflux, whereas MCT-1, responsible for lactate uptake, was expressed in 
OS cells. In agreement, silencing of MCT-1 by siRNA significantly affected the ATP 
production in OS cancer cells. Thus, cancer cells directly increase their mitochondrial 
biogenesis using this energy-rich metabolite that is abundantly provided by MSC as 
an effect of the altered microenvironmental conditions induced by OS cells. We also 
showed that lactate produced by MSC promotes the migratory ability of OS cells. 
These data provide novel information to be exploited for cancer therapies targeting 
the mutual metabolic reprogramming of cancer cells and their stroma.
INTRODUCTION
In addition to cancer cells, a number of reactive 
elements are present in the tumor microenvironment, 
including endothelial cells, immune cells, and fibroblast-
like stromal cells, playing a key role in the establishment 
and progression of the tumor [1]. In particular, the 
so-called cancer-associated fibroblasts (CAF) [2, 3], 
that are thought to originate from mesenchymal 
stem cells (MSC) [4, 5], have been described as key 
players in tumor metabolism. According to Otto 
Warburg’s findings, a hallmark of cancer cells is 
anaerobic glycolysis even under aerobic conditions. 
This behavior involves increased glucose consumption 
with consequent excessive production of lactate and 
H+, which causes a decrease of the extracellular pH 
to levels lower than in normal cells [6]. Indeed, most 
normal cells have a low rate of glycolysis followed by 
oxidation of pyruvate in mitochondria. The Warburg 
effect has important medical applications as high aerobic 
glycolysis has been clinically confirmed in most of 
malignancies.
Recent studies have shown that the Warburg effect 
is also activated in CAF that secrete energy-rich glycolytic 
metabolites, such as lactate and ketones. Cancer cells 
are able to uptake these metabolites and use them in the 
mitochondrial TCA cycle (the so-called reverse Warburg 
effect). Thus, there is a higher production of energy that 
therefore drives a large number of the cell’s energy-
requiring processes. This role of CAF as tumor feeders 
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has been reported in human breast [7, 8], prostate [9], and 
head and neck cancer [10].
CAF have also been established as an important 
component of osteosarcoma (OS) [11, 12], a highly 
malignant tumor of bone that typically affects children 
and adolescents. OS rapidly invades and destroys the 
surrounding bone and soft tissues, and in over 90% of 
the cases spreads to the lung within a few months after 
diagnosis. Radical surgical removal of the primary 
followed by aggressive multi-agent chemotherapy has 
been developed as the treatment of choice of OS, with a 
significant improvement in survival [13], although less 
toxic, more active agents are strongly felt to be needed. In 
this respect, most studies have focused on the molecular 
features of OS cells.
In this study, we considered the tumor 
microenvironment of OS as a whole and set out to 
inquire into the metabolic interactions between the 
stroma and tumor compartments. We employed OS cell 
lines such as Saos-2, HOS, and 143B. Our hypothesis is 
that the cellular metabolism of OS is deeply altered by 
MSC, affecting their behavior not only in the primary 
tumor site but also at the metastatic niche. Although the 
origin of OS is largely unknown, three specific aspects 
suggest the importance of MSC in the pathogenesis 
of this tumor. First, this tumor likely arises from 
transformed stem cells of mesenchymal origin [14]. 
Secondly, the number of circulating MSC is extremely 
high in OS patients [15]. The third consideration is 
that OS are able to recruit these circulating MSC [16]. 
Interestingly, MSC have been demonstrated to provide a 
fertile microenvironment for OS cells, promoting tumor 
progression and the formation of metastasis also through 
the secretion of signaling molecules [12, 17, 18]. We 
investigated the interaction between MSC and OS cells 
and, for the first time, were able to demonstrate the 
induction of aerobic glycolysis in MSC as a consequence 
of oxidative stress induced by OS cells. In turn, 
MSC enhance lactate secretion through an increased 
expression of MCT-4, and OS cells upload lactate 
through MCT-1, eventually raising their mitochondrial 
respiration to facilitate migration.
RESULTS
Reciprocal metabolic reprogramming of OS cells 
and MSC
To investigate the bioenergetic status of OS 
microenvironment, we employed a co-culture system 
of human OS cells (Saos-2) and human MSC from 
adipose tissue, and evaluated the mitochondrial activity 
as compared to homotypic cultures. To this end, 
Saos-2-MSC co-cultures and corresponding homotypic 
cultures were first immunostained with MitoTracker, 
a dye that detects functional mitochondria with active 
membrane potential. Figure 1A shows that homotypic 
culture of MSC displays a high mitochondrial activity 
that is decreased in the co-culture condition, suggesting 
that the presence of  Saos-2 cells induces a mitochondrial 
dysfunction in MSC. 
We next performed immunostaining of OS-MSC 
co-cultures with an antibody for the intact mitochondrial 
membrane (MAB1273), to evaluate the mitochondrial 
mass. Figure 1B shows that MSC increase mitochon-
drial mass in adjacent Saos-2 GFP (+) cells.
These results indicate that, in the co-culture 
system mimicking tumor microenvironment, MSC 
induce mitochondrial activity and biogenesis in OS cells. 
This increased mitochondrial power may sustain their 
increased metabolic demands. On the other hand, OS 
cells decrease mitochondrial power of MSC, inducing 
their metabolic switch toward an aerobic glycolytic 
pathway.
Saos-2 cells induce aerobic glycolysis in MSC
Next, we set out to investigate the glycolytic 
profile of MSC. To this end, we studied the expression 
of pyruvate kinase isoform 2 (PKM2), a key regulator 
of glycolysis and promoter of tumor growth [19]. For 
this purpose, MSC were incubated with conditioned 
medium (CM) derived from Saos-2 cells for 24 hours. 
Western blot analysis demonstrates that MSC activated 
by Saos-2-CM have a higher PKM2 expression, as 
compared to untreated MSC (Figure 2A), suggesting 
that the conditioned medium from Saos-2 cells 
induces a glycolytic switch in MSC. A shift towards 
a glycolytic phenotype is also supported by the real 
time PCR analysis for the glucose transporter GLUT1 
mRNA in CM-activated MSC versus not activated 
MSC. Figure 2B (left plot) shows increased GLUT1 
expression in MSC after activation with Saos-2-CM, 
suggesting an enhanced glucose uptake and increased 
glycolysis.
Next, we investigated the expression of MCT-4, 
the passive lactate-proton shuttle responsible for the 
lactate efflux. We found that the CM-treatment increased 
the gene expression of MCT-4 (Figure 2B, right plot). 
In agreement with these data, immunofluorescence 
analysis demonstrates that MSC in co-culture with OS 
cells show higher MCT-4 expression, as compared to 
the corresponding homotypic culture (Figure 2C). Given 
that MSC undergo a glycolytic switch following their 
activation by OS cells, we next investigated the secretion 
of lactate, the final product of glycolysis. Importantly, we 
observed that MSC, after activation with CM from 2 OS 
cell lines (Saos-2 and HOS cells), show an increased 
secretion of lactate, with respect to untreated MSC 
(Figure 2D).
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Figure 1: MSC-Saos-2 cell co-cultures exhibit changes in the mitochondrial state. (A) MSC decrease their mitochondrial 
activity in co-cultured Saos-2 cells. Co-cultures of Saos-2 GFP (+) positive cells (green) and MSC were immunostained with 
MitoTracker (red). Note that co-culture with OS cancer cells induces a significant decrease in the mitochondrial activity of MSC (lower 
row), as compared to MSC cultured alone (top row). Importantly, images were acquired using identical exposure settings. White asterisks 
indicated Saos-2 GFP (+) positive cells. Original magnification, 20x; scale bar 10 μm. (B) MSC induce an increase in mitochondrial 
mass in co-cultured Saos-2 GFP (+) positive cells (green). Homotypic cultures of Saos-2-GFP (first row, merge first panel) and their 
co-culture with MSC (lower row, merge first panel) were immunostained with an anti-intact mitochondrial membrane antibody (red). 
DAPI was used to stain nuclei (blue). Note that in co-culture, the mitochondrial mass is clearly increased in Saos-2 cells as compared to 
the respective homotypic culture. Importantly, images were acquired using identical exposure settings. Original magnification, 20x. Scale 
bar 20 μm.
Oncotarget7578www.impactjournals.com/oncotarget
Figure 2: Saos-2 cells drive aerobic glycolysis in adjacent MSC. (A) Upregulation of PKM2 in MSC activated by OS cells. 
Cell lysates were prepared from MSC activated by conditioned medium from serum-starved Saos-2 cells or untreated, non-activated MSC. 
Lysates were analyzed by Western blot with an anti-PKM2 specific antibody. Note the upregulation of PKM2 in tumor-activated MSC, as 
compared to untreated MSC. Normalization was done by actin immunoblot. (B) Gene expression analysis of GLUT1 (left plot) and MCT-4 
(right plot) by RT-PCR. Note that MSC cultured with CM from Saos-2 cells, show significantly higher levels of the GLUT1 and MCT-4 genes, 
versus non-activated MSC. Glut1, p=0.0092; MCT-4, p=0.0071. (C) Upregulation of MCT-4 expression was validated by immunofluorescence 
analysis. Homotypic cultures of MSC (top row) and Saos-2 GFP cells (middle row) and Saos-2-MSC heterotypic cultures (lower row) were 
immunostained with MCT-4 antibodies. DAPI was used to stain nuclei (blue). Note that the MCT-4 expression (red) is clearly increased 
in MSC in co-culture condition, as compared to MSC cultured alone. Importantly, images were acquired using identical exposure settings. 
Original magnification, 20x. Scale bar 40 μm. (D) Tumor-activated MSC show increased lactate secretion. MSC were incubated with CM 
obtained from OS cells (Saos-2 or HOS) for 48 hours. Then, cells were carefully washed and incubated in fresh serum-free medium for an 
additional 24 hours. Lactate assay was performed on this culture medium. Note that lactate production is significantly increased in MSC, after 
activation with conditioned media from Saos-2 cells (left plot) and HOS cells (right plot). Values were normalized by cell numbers *p<0.05.
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OS cells uptake lactate produced by 
activated MSC
We next investigated the expression of MCT-1, the 
monocarboxylate transporter for the uptake of lactate, in 
OS cells, by real time PCR. Saos-2 cells, after incubation 
with CM of activated MSC, significantly increased the 
expression of MCT-1, as compared to untreated cells 
(Figure 3A).
These results were confirmed by immunofluo-
rescence, showing MCT-1 upregulation in OS cells 
co-cultured with MSC, as compared to OS cells cul-
tured alone (Figure 3B). These results suggest that OS 
cells are able to uptake lactate, a high-energy metabo-
lite which is a substrate for mitochondrial oxidative 
phosphorylation.
To assess if the metabolic reprogramming observed 
in vitro also occurs in vivo, 143B human OS cells were 
injected into the flanks of SCID mice. After three weeks, 
tumors were collected and immunohistochemistry was 
performed on paraffin sections for the expression of 
MCT-4, the transporter for lactate extrusion. As shown in 
Figure 3C, MCT-4 was highly expressed in the stromal 
compartment of the xenograft tumors. These findings 
indicate that, also in vivo, glycolysis preferentially 
occurs in the stromal compartment, leading to increased 
MCT-4 expression. This suggests that stromal cells avoid 
the internal accumulation of lactate, making it available 
for OS cells. Thus, our data indicate that tumor cells 
induce important metabolic alterations in adjacent stromal 
cells, with impairment of their mitochondrial function and 
enhancement of aerobic glycolysis.
Aerobic glycolysis in MSC is ROS-dependent
Oxidative stress is known to drive tumor spread 
and invasion [20, 21] and this phenomenon has already 
been shown in stromal fibroblasts from breast and prostate 
cancer and suggested as a starter of glycolytic switch 
[9, 22]. Figure 4A (representative plot) shows that over 
70% of MSC cells exposed to OS-conditioned medium 
have higher levels of ROS, with respect to non-activated 
MSC. Interestingly, the basal ROS levels of MSC were 
restored when cells were treated with the antioxidant 
N-Acetyl-Cystein (NAC) (Figure 4A, graph bar). 
Accordingly, the expression of the glucose transporter 
GLUT1 was also decreased in the presence of NAC 
(Figure 4B). These findings indicate that MSC undergo 
aerobic glycolysis as a consequence of a ROS-dependent 
interplay with OS cancer cells.
Lactate promotes mitochondrial biogenesis and 
oxidative phosphorylation in Saos-2 cells
Next, we evaluated if lactate is sufficient per se 
to induce the effects observed in the co-culture system, 
i.e. the promotion of mitochondrial biogenesis. To this 
end, we treated homotypic cultures of Saos-2 cells with 
10 mM lactate for 48 hours. After treatment, cells were 
fixed and immunostained with an antibody against the 
intact mitochondrial membrane (MAB1273). As shown 
in Figure 5A, lactate administration strongly increases 
the mitochondrial mass of OS cells. In addition, we 
performed Western blot analysis with a panel of antibodies 
against OXPHOS complex subunits. These subunits must 
be properly assembled to allow a functional oxidative 
phosphorylation. As shown in Figures 5B and 5C, upon 
lactate treatment, OS cells show a strong increased 
expression of complexes I, II, IV, and V.
Finally, we evaluated if the uptake of lactate that 
is used by Saos-2 cells for mitochondrial biogenesis, 
is mediated by MCT-1. For this purpose, we silenced 
MCT-1 expression in Saos-2 cells by a specific siRNA. 
Once we confirmed the significant inhibition of 
MCT-1 mRNA after transfection (Figure 5D), we observed 
that MCT-1 silencing strongly affected the ATP content 
of Saos-2 cells treated with lactate. Figure 5E shows 
that Saos-2 cells treated with an unspecific siRNA or 
untreated display a significant increase in ATP content 
after incubation with lactate. Conversely, no significant 
increase was observed in Saos-2 cells treated with MCT-1 
specific siRNA (Figure 5E). These results suggest that OS 
cells are able to uptake lactate through MCT-1 and utilize 
this metabolite for their Krebs cycle and ATP synthesis, 
therefore increasing their bioenergetic status.
Lactate increases the migratory ability of 
OS cells
We then examined the effects of activated MSC 
on the migratory ability of Saos-2 and HOS cells. For 
this purpose, MSC were activated by treatment with 
OS cell-derived conditioned media. Then, to prepare 
conditioned media from activated MSC, MSC were 
rinsed and incubated for 24 hours in serum-free media. 
OS cells were treated with conditioned medium from 
MSC previously activated, and their migratory ability was 
assessed using a modified Boyden chamber. We observed 
that CM from activated MSC significantly enhances 
cancer cells migration relative to non-activated cells 
(Figure 6A). Next, we performed an in vitro scratch assay 
(Figure 6B, representative image) of Saos-2 and HOS 
cells treated with lactate 10 mM for 24 hours. Lactate 
treatment significantly increased the migration of OS cells 
with respect to untreated cells (Figure 6C). These data 
indicate that MSC are able to promote the migration of 
OS cells, and this effect is mimicked by lactate treatment 
(Figure 6D).
DISCUSSION
The tumor microenvironment is a cellular matrix 
consisting of cells, soluble factors, signaling molecules 
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Figure 3: Tumor-activated MSC induce high MCT-1 expression in Saos-2 cells. (A) The result is observed by RT-PCR, 
*p<0.05. (B) MCT-1 is upregulated in Saos-2-GFP cells co-cultured with MSC. MCT-1 immunofluorescence was performed in homotypic 
cultures of MSC (top row) and Saos-2 cells (middle row), and in the MSC-Saos-2 cell co-culture system (lower row). Note that MCT-1 
expression (red staining) is mainly present in the OS green cells. Merged image is shown in the middle and lower panels. DAPI was used 
to stain nuclei (blue). Importantly, images were acquired using identical exposure settings. Original magnification, 20x. Scale bar 40 μm. 
(C) MCT-4 immunohistochemistry was performed on mouse tumor xenograft of human 143B cells. Note that tumor stroma from the host 
is strongly stained for MCT-4 (brown), while the tumor compartment is poorly stained. Original magnification 20x; scale bar 50 μm (upper 
row). Original magnification 60x and scale bar 20 μm (lower row).
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Figure 4: Oxidative stress is increased in activated MSC cells. (A) MSC cells were exposed to conditioned medium from OS 
cells and evaluated by flow cytometry using DCFH-DA (as a measure of total ROS released). The representative plot of the flow-cytometric 
analysis shows that about 70% of MSC exposed to the Saos-2 cells-conditioned medium (continuous dark line) exhibit a fluorescence 
intensity higher than that observed in untreated MSC (dashed light line). The histogram bars show the ratio between “MC of activated 
MSCs” and “MC of non-activated MSC” (mean ± SEM). The ROS production in MSC challenged with the conditioned medium of Saos-2 
cells was significantly increased in comparison to untreated MSC, but the basal activity of MSC is restored when an antioxidant, i.e. NAC, 
is introduced into the culture system. **p= 0.002; ***p= 0.0005. MC: mean channel of fluorescence intensity. (B) Pre-treatment of MSC 
with the anti-oxidant NAC decreases the expression of GLUT-1, suggesting that the shift to the Warburg metabolism with increased uptake 
of glucose depends on oxidative stress, *p<0.05.
and extracellular matrix that supports tumor growth and 
invasion, protects the tumors from host immunity, fosters 
therapeutic resistance, and provides a niche for dormant 
metastases to thrive. As our understanding of the role 
of the tumor microenvironment in cancer continues to 
evolve, the complexity of the interactions between cancer 
cells and their microenvironment has become increasingly 
apparent. Tumor microenvironment is a dynamic milieu: 
non-immune mesenchymal cells, such as fibroblasts 
and their precursors MSC, play an important role in 
tumor microenvironment where they are “educated” by 
neoplastic cells and, vice versa, influence the behavior of 
cancer elements. Controversial results have been reported 
when MSC injected into mice resulted either in promotion 
[23, 24, 25] or inhibition [26, 27] of tumor growth. 
Regarding OS, it has been reported that MSC exert a pro-
inflammatory effect on cancer cells by producing soluble 
factors that promote cell proliferation [4, 28]. However, 
the effect of MSC within tumors seems unpredictable and 
dependent on microenvironment signals [29].
In this study, we considered two metabolic 
compartments in OS, cancer cells and reactive MSC. 
Our results suggest a model of metabolic coupling by 
which MSC, after having been “activated” by the OS 
cells, increase the aggressive behavior of cancer cells. In 
particular, we showed that tumor cells induce oxidative 
stress, via ROS production, in adjacent MSC, triggering 
a metabolic shift to aerobic glycolysis. Moreover, we 
also showed that MSC in contact with OS cells undergo 
activation and produce lactate, as described in the 
Warburg effect. On the other hand, cancer cells increase 
their mitochondrial activity and their mitochondrial mass 
by utilizing lactate by an increased MCT-1 expression. 
This pathological process involving MCT-1 mimics the 
physiological metabolic situation observed in skeletal 
muscle fibers, previously described [30]. Our data 
indicate that the inhibition of MCT-1 significantly affects 
the energy metabolism of cancer cells, by decreasing 
ATP production. In agreement, the importance of MCT-1 
in OS has been investigated in a recent study, showing 
that downregulation of MCT-1 inhibits tumor growth and 
metastasis, and enhances chemotherapeutic efficacy [31].
Moreover, we also found in vivo evidence for 
mitochondrial dysfunction in the stromal compartment 
of OS mouse tumor xenografts. Indeed, the 
immunohistochemistry analysis performed on murine 
tumor sections revealed that MCT-4 was detected only 
in the stromal host-derived cells. These results suggest 
not only that OS cells are able to recruit reactive stromal 
elements, but also that these cells can be induced to 
undergo aerobic glycolysis and fuel the tumor metabolic 
needs, in line with results previously observed in breast 
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Figure 5: Lactate treatment promotes mitochondrial biogenesis and oxidative phosphorylation in OS cells. (A) Homotypic 
cultures of Saos-2 cells were treated with or without 10 mM of lactate for 48 hours. Cells were fixed and immunostained with an antibody 
against the mitochondrial membrane (red). Note that lactate treatment increases mitochondrial mass in Saos-2 cells, mimicking the co-culture 
condition. Importantly, images were acquired using the same exposure settings. Original magnification, 20x; scale bar 50 μm. (B) Immunoblot 
analysis of V-ATP5A, III-UQCRC2, II-SDHB, IV-COXII and I-NDUFB8 was performed on Saos-2 cells with or without 10 mM of lactate for 
48 hours. Actin immunoblot was used for normalization. (C) The plot reports the densitometric quantitation (ratio of each protein:actin). Note 
that complex I, complex II, complex IV and V are upregulated in Saos-2 cells after treatment with lactate, as compared to the untreated samples. 
*p<0.05. (D) Saos-2 cells were treated with MCT-1 specific siRNA and, after 24 hours, the MCT-1 mRNA expression levels were evaluated. The 
silencing significantly inhibited MCT-1 expression, *p<0.05 vs not treated cells. (E) Homotypic cultures of Saos-2 cells transfected with MCT-1 
siRNA, with not-targeting siRNA, or untreated, were incubated with or without 10 mM of lactate for 48 hours. Then, ATP content was evaluated. 
The silencing of MCT-1 expression impaired the increase in ATP content induced by lactate treatment (*p<0.05 treated with lactate vs untreated).
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Figure 6: MSC-activated Saos-2 and HOS cells acquire increased migratory capacity. (A) We assessed whether tumor-
activated MSC were able to increase the migration of Saos-2 and HOS cells, using a modified Boyden chamber assay. As a control, serum-
free CM from non-activated MSC was placed in the lower chambers. Note that CM of previously activated MSC was able to increase the 
migratory capacity of OS cells, *p<0.05. (B and C) We analyzed Saos-2 and HOS migration by an in vitro scratch assay. OS cells were 
plated to create a confluent monolayer, which was later scraped. Images were acquired with a phase-contrast microscope. To capture 
the same field during the image acquisition, marks next to the scratch were used as reference points. (B) Saos-2 cells were treated with 
or without 10 mM lactate, as indicated. Images were acquired at 0 and 24 hours. Note that Saos-2 treated with lactate migrate faster, as 
compared to untreated Saos-2 cells. Original magnification, 10x. (C) Quantification of cell migration after scratch assay of Saos-2 cells (left 
plot) and of HOS cells calculated as % closure (right plot). (D) Proposed model of the metabolic circuit between MSC and OS cells. The left 
drawing represents the primary tumor or the metastatic site that includes tumor cells and MSC as stromal compartment. The right drawing 
explains in detail the reciprocal metabolic reprogramming: tumor cells induce MSC to undergo Warburg metabolism leading to increased 
uptake of glucose and its conversion to lactate. Stromal cells extrude lactate through the shuttle MCT-4. OS cells are able to uptake this 
metabolite through the MCT-1 transporter, and utilizing it as fuel for their TCA cycle, as well as for cell migration.
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and head and neck cancer [10, 32]. In addition, we further 
demonstrated that activated-MSC induce tumor migration 
and that lactate is directly responsible for such increased 
migratory capacity of cancer cells. A previous study had 
shown that MSC drive proliferation and metastasis in OS 
through IL-6/STAT3 signaling pathway [18]. It remains to 
be determined if the STAT3 pathway plays a role in our 
model.
Here, for the first time, we have addressed the role 
of MSC as modulators of OS metabolism and behavior 
(Figure 6D). In fact, we demonstrated that MSC play a role 
as tumor cells feeders after their metabolic reprogramming 
to a glycolytic phenotype (reverse Warburg phenotype), 
while, at the same time, tumor cells undergo mitochondrial 
biogenesis and increased mitochondrial activity. The 
importance of the increased mitochondrial mass and 
bioenergetics in tumorigenesis has been also confirmed 
by recent findings regarding the mitochondrial citrate 
transporter CIC/ SLC25A1 [45, 46]. CIC is necessary 
for the Krebs cycle and oxidative phosphorylation. 
Interestingly, the authors demonstrated that the genetic 
CIC inhibition induced the Warburg effect in cancer cells, 
and inhibited tumor growth.
Several studies have shown the importance of 
resident mesenchymal reactive cells in supporting tumor 
progression and metastasis in prostate, breast [33], ovarian 
and colon cancer [34, 35]. It has been recently shown in 
an animal model that the administration of exogenous 
MSC may promote tumor engraftment and lung 
colonization, leading to OS growth and metastasis [12]. 
These findings, together with the evidence of an increased 
number of circulating MSC observed in OS patients, 
and the interesting observation that MSC are capable to 
facilitate cancer migration through heterotypic interactions 
with tumor cells [36, 37] [12], suggest that MSC may 
be important for metastases development, by providing 
a supportive niche in certain organs. Additionally, the 
emerging cancer stem cell hypothesis has complicated 
the scenario. Indeed, it has been reported the presence of 
stem-like cells, implicated in tumorigenesis, metastasis 
and drug resistance [38, 39]. Speculatively, MSC may also 
exist in the cancer stem cell niche, perhaps playing a key 
role in the subsistence of the microenvironment. Here, we 
propose a cellular model applicable to the primary tumor 
site and to the metastatic environment.
Although these data clarify some aspects of the 
interplay between MSC and tumor cells in aerobic 
condition, at the same time they bring intricacy to the 
system. As solid tumors have more hypoxic and acidic 
microenvironments than normal tissue [40], further 
investigations should be extended to MSC metabolic 
behaviors under hypoxic condition and at different pH 
conditions.
In conclusion, given that osteosarcomas are 
rare tumors with poor prognosis because of metastatic 
dissemination, it is of vital importance to understand the 
interactions between MSC and their niche to possibly find 
therapeutic strategies.
METHODS
Cell cultures and stable transfection
Human mesenchymal stem cells were purchased 
from ATCC (ATCC® PCS-500-011™) and characterized 
as described [41, 42]. The OS cell lines Saos-2 (ATCC® 
HTB-85™) and HOS (ATCC® CRL-1543™) were from 
ATCC, and the cell line 143B was a kind gift from 
Dr. Michiel Pegtel (VU University Medical Center, 
Amsterdam, NL). All cells were maintained in RPMI 
with 10% fetal bovine serum (FBS) and penicillin 
100 units/ml-streptomycin 100 μg/ml. For co-culture 
experiments, MSC and Saos-2 were plated on glass 
cover slips in 12-wells plates in 1 ml of complete 
medium. OS cells were plated within 2 hours of MSC 
plating. Experiments were performed at a 3:1 MSC- 
to-OS cell ratio. As controls, monocultures of MSC and 
OS cells were seeded using the same number of cells 
as the corresponding co-cultures. The day after plating, 
medium was changed to RPMI with 10% NuSerum (BD 
Biosciences) a low protein alternative to FBS, and Pen-
Strep. Cells were maintained at 37°C in a humidified 
atmosphere containing 5% CO
2
. To obtain activated 
MSC, cells were grown to 80% confluence and treated for 
24 hours with conditioned medium from Saos-2 cells in 
serum-free medium for 48 hours. Activated Saos-2 cells 
were obtained by incubating them for 24 hours with 
conditioned medium of MSC previously activated by 
tumor cells. Saos-2 cells were used to generate a cell 
line overexpressing the GFP tag. A plasmid purchased 
from Addgene was employed, and cells were transfected 
with Fugene6 transfection reagent (Roche) following the 
manufacturer’s instructions. Transfected OS cells were 
selected with G418/Geneticin (Life Technologies).
Mitochondrial staining
To evaluate the mitochondrial activity, cells were 
stained with MitoTracker Orange CMTMRos (M7510) 
(Invitrogen). Lyophilized MitoTracker was dissolved in 
DMSO to generate a 1 mM stock solution that was diluted 
into serum-free DMEM at a final concentration of 25 nM. 
Briefly, cells were cultured for 48 hours and then stained 
with MitoTracker for 5 minutes at 37°C. Cells were 
washed in PBS and fixed with 4% paraformaldehyde for 
10 minutes.
Immunocytochemistry
Briefly, after 15 minutes fixation in 4% 
paraformaldehyde, cells were permeabilized for 
10 minutes with PBS containing 0.2% BSA and 0.1% 
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TritonX-100. Then, cells were incubated for 10 minutes 
with NH
4
Cl in PBS to quench free aldehyde groups. 
Primary antibody was incubated overnight. After washing, 
cells were incubated with fluorochrome-conjugated 
secondary antibodies for 1 hour. Finally, slides were 
washed, incubated with the nuclear stain and mounted. 
Antibodies were as follow: antibody for the surface 
of intact mitochondria (1:300; MAB1273, Millipore); 
MCT-4 (1:100; Santa Cruz); secondary antibody for 
immunofluorescence was Alexa orange-red 546 nm 
(1:500; Invitrogen).
Western blotting
Cells were harvested in lysis buffer (RIPA buffer) 
containing protease and phosphatase inhibitors and 
centrifuged at 13,000x g for 10 minutes at 4°C to remove 
insoluble debris. Protein concentrations were analyzed 
using Bradford assay (Biorad). 30 μg of proteins were 
loaded and separated by SDS-PAGE and transferred to a 
0.2 μm nitrocellulose membrane (Fisher Scientific). After 
blocking for 1 hour in TBST (10 mM Tris-HCl pH 8.0, 
150 mM NaCl, 0.5% Tween-20) with 5% non-fat dry milk, 
membranes were incubated with the primary antibody for 
1 hour or overnight, washed and incubated for 1 hour with 
horseradish peroxidase-conjugated secondary antibodies. 
The membranes were washed and incubated with an 
enhanced chemi-luminescence substrate (ECL; Thermo 
Scientific). The antibodies were as follow: β-actin (1:5000; 
Sigma); PKM2 (1:200; Cell Signaling); OXPHOS (1:500; 
MitoSciences).
Gene expression analysis
Gene expression was analyzed after 24 hours 
of culture by quantifying gene transcripts. RNA was 
extracted with NucleoSpin RNA II (Macherey-nagel, 
Düren, Germany) and the retrotranscription was performed 
with MuLV Reverse Transcriptase (Applied Biosystems, 
Foster City, Ca, USA). Real-Time Polymerization Chain 
Reaction (Real-time PCR) was performed by amplifying 
1 μg of cDNA using the Light Cycler instrument and the 
Universal Probe Library system (Roche Applied Science, 
Monza, Italy). Probes and primers were selected using the 
web-based assay design software (ProbeFinder: http://www 
.roche-applied-science.com). The protocol of amplification 
was: 95°C for 10 minutes; 95°C for 10 seconds, 60°C for 
30 seconds, and 72°C for 1 second for 45 cycles; 40°C 
for 30 seconds. β-actin was used as housekeeping gene to 
normalize the expression of the genes of interest [43]. The 
results were expressed as a ratio between gene of interest and 
β-actin gene. All experiments were performed in triplicates.
Measurement of reactive oxygen species
5-(and 6-) carboxy-2’,7’-dichlorodihydrofluorescein 
diacetate (CM-H2DCFDA; C369) was from Invitrogen. 
CM-H2DCFDA is a cell-permeable molecule used to 
measure intracellular ROS. MSC were incubated with 
10 μM CM-H2DCFDA for 5 minutes at 37°C, then 
washed with PBS and analyzed by flow cytometry. To 
control for staining specificity, cells were also treated 
with 10 mM of NAC overnight prior to CM-H2DCFDA 
incubation. The production of ROS by MSC challenged 
with the conditioned medium of OS cell line Saos-2 was 
evaluated by measuring fluorescence emission following 
the conversion of 2’,7’-dichlorofluorescin-diacetate 
(DCFH-DA) into DCF by ROS produced intracellularly. 
All samples were analyzed on a flow cytometer EPICS 
XL-MCL (Beckman Coulter, Fullerton, CA, USA). The 
acquisition gate was established based on forward and 
side scatter parameters, and each sample was run until 
10,000 events were acquired in the gate analysis. The 
fluorescent signal generated by ROS production was 
recorded as mean channel of fluorescence intensity (MC), 
and the effect of the conditioned media was expressed 
as a ratio between “MC of activated MSC” and “MC of 
non-activated MSC”.
L-lactate assay
Lactate was measured in the culture media with 
lactate assay kit (EnzyChrome, BioAssay Systems) 
according to the manifacturer’s instruction.
Animal studies
Animals were housed and maintained in a pathogen-
free environment/barrier facility at the University of 
Modena and Reggio Emilia, Modena, Italy. 1x106 of 
143B human cells were subcutaneously injected with 
reduced growth factor matrigel (BD Biosciences) in 
five-week-old severe combined immunodeficient 
(SCID)-bg/bg male mice (Charles River Laboratories 
International). Mice were sacrificed after three weeks, and 
tumor samples were collected for histological analysis. 
The Animal Ethics Committee of Modena approved all 
the experimental protocols.
Immunohistochemistry
Five-micron paraffin sections were stained with 
MCT-4 antibody. Sections were dewaxed, rehydrated 
through graded ethanol series, and antigen retrieval 
was performed with 10 mM citrate buffer, pH 6.0 for 
15  minutes using a microwave. The cooled sections were 
blocked with 3% hydrogen peroxide and next incubated 
with 5% BSA for 1 hour, followed by primary antibodies 
overnight at 4°C. Biotinylated secondary antibodies fol-
lowed by streptavidin-horseradish peroxidase conjugated 
were from Dako. Immunoreactivity was revealed with the 
DAB solution (Dako). Sections were counterstained with 
hematoxylin.
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ATP assay
Specific gene silencing was obtained by siRNA 
technology associated with electromicroporation 
technology. Cells were trypsinized at semi-confluence and 
counted. 100 microliters of cell suspension containing 2x106 
cells and 4 nmol of specific or control siRNA (Dharmacon) 
were transferred into a 1-mm cuvette, and an electrical 
field was applied to induce siRNA cellular internalization 
(MicroPorator MP-100; Digital BioTechnology). For 
the RNA isolation, after electroporation, Saos-2 cells 
were transferred into 2 mL of complete growth medium 
and seeded in 12-well plates (3x105 cells per well). After 
24 hours, cells were lysed and RNA was extracted as 
described above. For ATP assay, after electroporation, 
Saos-2 cells were transferred into 3 mL of complete growth 
medium and seeded in 6-well plates (8x105 cells per well). 
For the analysis of ATP content, cells were lysed by using 
boiling ATP lysis buffer [0.1 M Tris(hydroxymethyl)
aminomethane (Tris base) (Sigma) and 2 mM EDTA 
adjusted to pH 7.75 with acetic acid (Sigma) and 2.5% 
Dodecyltrimethylammonium bromide (Sigma)]. The ATP 
content was measured with the ATP determination kit 
(Molecular Probes). The luciferase signal was normalized 
with the Log of the total protein concentration measured 
by Bradford assay (Bio-Rad Laboratories). All experiments 
were performed in triplicates.
Migration assay
Transwells with uncoated permeable support and 
8 μm pores were used. 4x104 viable Saos-2 cells were 
seeded per well and incubated in 5% CO
2
 at 37°C for 
12 hours. All functional experiments were performed in 
triplicates.
In vitro scratch assay
Cells were plated onto the 60-mm dish to create 
a confluent monolayer. Cell monolayers were scraped 
in a straight line to create a ‘‘scratch’’ with a p200 pipet 
tip. Dishes were placed in a tissue culture incubator at 
37oC for 24 hours. The images acquired for each sample 
were photographed under a phase-contrast microscope. 
To obtain the same field during the image acquisition, 
markings were created as reference points close to 
the scratch. The rate of migration was measured by 
quantifying the number of cells that moved from the edge 
toward the center of the scratch. Image J software was 
used to measure the wound closure [44].
Statistical analysis
Quantitative results were expressed as arithmetic 
mean plus or minus the standard error of the mean (SEM) 
from at least 3 independent experiments. Mann-Whitney 
test was performed as unpaired comparison for two 
independent variables. All p values <0.05 were considered 
as statistically significant. t-test was also applied when 
appropriate. The statistical analysis was performed by 
StatView5.01 software (SAS Institute Inc., Cary, NC). The 
changes in ROS production after exposure to conditioned 
media were evaluated by a nonparametric test for paired 
data (Wilcoxon signed rank test).
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